Munich, Germany, Oct 10, 2018. apceth Biopharma is proud to announce that it will be presenting its latest results on apceth-201 in graft-vs-host-disease (GvHD) at this year’s ESGCT Annual Congress “Changing Modern Medicine: Stem Cells & Gene Therapy”. The meeting will take place in Lausanne, Switzerland, on October 16-19, 2018.
apceth‘s poster is titled: “Human Mesenchymal Stem Cells Genetically Engineered to Express Alpha-1 Anti-Trypsin (apceth-201) Confer a Long-Term Survival Benefit in Lethal Mouse Models of Graft-Versus-Host-Disease”. It has poster number P126 and will be presented during the session on Thursday, October 18.
For further information on ESGCT Annual Congress, please visit https://www.esgct.eu/Congress/Current-Congress.aspx